Tema " RECEPTIVIDADE ENDOMETRIAL. ESTADO DA ARTE"
LOCAL CENTRO DE CONVENÇÕES REBOUÇAS - ALA NOVA - SALÃO TURQUESA
O Prof. Simón é o Titular de Obstetricia e Ginecologia na Universidade de Valência e Professor Adjunto de Ob/Gyn da Escola de Medicina da Universidade de Stanford nos Estados Unidos, além de Diretor do Instituto Valenciano de Infertilidade. Suas linhas de pesquisa envolvem importantes conceitos e práticas relacionadas com a receptividade do endométrio, endometriose, e células-tronco.
APOIO INSTITUCIONAL :
Resumo do C. V.
Since 1991, his basic and clinical research has
contributed to the advance of Reproductive Medicine, specifically in the
understanding of human endometrial receptivity, embryo viability, embryonic
implantation and endometriosis. He discovered the relevance of the
interleukin-1 system in embryonic implantation (Simon et al., JCEM 1993; 1994;
Endocrinology 1994; BOR 2006). He demonstrated the deleterious effect of high
hormonal levels in patients with high response to gonadotrophins thus modifying
the established clinical practice (HR1995; Fertil Steril 1996; 1998). He
pioneered the concept that human oocytes are affected in endometriosis (HR
1994; Fertil Steril 2000) thus changing the clinical practice in oocyte
donation. He proposed a new embryo coculture system, now successfully used
worldwide (JCEM 1996; Fertil Steril 2003). His basic research on endometrial
receptivity led him to create and patent a customized array named endometrial
receptivity array (ERA) for the molecular diagnosis of endometrial receptivity
(Fertil Steril 2011, 2013). He has been awarded “Prize Jaime I 2011 in Medical
Investigation” for his pioneering work in
human endometrial receptivity disorders.
In an independent bibliometric analysis considering publications in
Reproductive Biology between 2003 and 2005, Carlos Simon was identified as the
9th most productive author in the world (Gonzalez-Alcaide G et al., Fertil
Steril 90:941-56,2008).
Since 2001, he has expanded his research into the field of stem cells,
resulting in the derivation, characterization, and registration in the Spanish
National Stem Cell Bank (BNLC) of ten human embryonic stem cell (hESC) lines (http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-ejecucion/fd-programas-investigacion/fd-investigacion-terapia-celular-medicina-regenerativa/banco-nacional-lineas-celulares.shtml). He derived the first two
hESC in Spain (Fertil Steril 2005) and described a new system for freezing hESC
in the absence of animal contaminants. He derived VAL-6M, the first line with a
monogenic disorder (Myotonic Dystrophy Type I) in Spain. Also, he obtained the
first two hESC lines without destroying the human embryo using blastomere
biopsy and demonstrated the lack of genetic diversity in the most common used
hESC in the world (Mosher JT et al. N Engl J Med 2010). Finally, he reported
the identification and characterization of human endometrial stem cells
(Cervelló et al., PLoS ONE. 2010, 2011, 2012)
As Principal Investigator, his work has been funded through 16 projects
sponsored by the Spanish Government, 4 by the Valencian Government, including 2
PROMETEO (granted to prestigious scientists) and 16 projects by international
organizations, American Universities and private companies.
Metrics:
At ISI Web of Knowledge (http://apps.isiknowledge.com) Prof. Carlos Simon is author of 348 publications in international
peer-review journals, adding up to an accumulated impact factor of 1,541.47. His papers have received a
total of 11,139 cites with an
average of 32 cites/paper. His H-Index
is 60 and he is editor of 15 books. He has been Director of 28 PhD Thesis all qualified with
"Cum Laude", including 4
PhD Awards of Excellence and 3
European PhD. As inventor, his research has originated 13 Patent Applications, leading to the creation of IVIOMICS a
biotech company http://iviomics.com.
He has been Director of 28 PhD Thesis all
qualified with "Cum Laude", including 4 PhD Awards of Excellence and
3 European PhD.
As inventor, his research
has originated 13 Patent Applications, leading to the creation of IVIOMICS a
biotech company http://iviomics.com.
